Elsevier

Experimental Neurology

Volume 248, October 2013, Pages 148-156
Experimental Neurology

AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model

https://doi.org/10.1016/j.expneurol.2013.06.002Get rights and content

Highlights

  • Gene transfer of CDNF by AAV rescued 6-OHDA induced behavioral deficits.

  • The therapeutic effects of AAV2.CDNF appeared to be long-term and persistent.

  • We attempted PET imaging technology to determine the DAT activity.

Abstract

Parkinson's disease (PD) is an aging-associated neurodegenerative disorder with progressive pathology involving the loss of midbrain dopaminergic neurons. Neurotrophic factors are promising for PD gene therapy; they are integrally involved in the development of the nigrostriatal system. Cerebral dopamine neurotrophic factor (CDNF) was recently discovered to be more selective and potent on preserving dopaminergic neurons than other known trophic factors. The present study examined the neuroprotective and functional restorative effects of CDNF overexpression in the striatum via recombinant adeno-associated virus type 2 (AAV2.CDNF) in 6-hydroxydopamine (6-OHDA) injected rats. Striatal delivery of AAV2.CDNF was able to recover 6-OHDA-induced behavior deficits and resulted in a significant restoration of tyrosine hydroxylase immunoreactive (TH-ir) neurons in the substantia nigra pars compacta (SNpc) and TH-ir fiber density in the striatum. PET analyses with [11C]-2β-carbomethoxy-3β-(4-fluorophenyl)-tropane ([11C]β-CFT) probes suggested functional recovery of dopaminergic (DA) neurons. Our results indicate that striatal administration of AAV2.CDNF was able to provide effective neuro-restoration in the 6-OHDA-lesioned nigrostriatal system and that it may be considered for future clinical applications in PD therapy.

Introduction

Approximately 1% of the population aged 65 years or older is diagnosed with Parkinson's disease (PD). Occurrence is even higher in people older than 85 years; approximately 4–5% are diagnosed with this progressive neurodegenerative disorder (Farrer, 2006). The typical clinical symptoms of PD include resting tremor, rigidity, akinesia and postural instability; these symptoms become worse in PD patients as the disease progresses. The pathological hallmark of PD is the prominent loss of dopaminergic (DA) neurons of the substantia nigra (SN) that project to the striatum, and intraneuronal protein inclusions known as “Lewy bodies” may be observed (Burke, 1999). The degree of DA neuron loss has been correlated with reduced DA transporter (DAT) levels (Dauer and Przedborski, 2003). DAT is a presynaptic protein found at terminal dopaminergic neurons that regulates dopamine concentration in the synaptic cleft by allowing re-uptake of dopamine by presynaptic neurons (Nirenberg et al., 1996). Recently, chemical probes targeting DAT have been increasingly considered to be more accurate markers of DA neuronal function, especially in the PET-based neural imaging (Shih et al., 2006).

As the etiology of PD remains unclear, the current available treatments are heteropathic and aim to relieve symptoms. Therefore, novel therapies for slowing or reversing disease progression, and specifically those preventing neurodegeneration, are urgently needed (Burton et al., 2003). Neurotrophic factors, which are designated as a collective subset of growth factors that promote neuronal survival and stimulate neuritic outgrowth of specific types of neurons, are preferred to restore DA neuronal function in degenerative conditions. Recently, a new family of neurotrophic factors has been identified, which are particularly valuable for the treatment of PD. Two members of this family are mesencephalic astrocyte-derived neurotrophic factor (MANF) and cerebral dopamine neurotrophic factor (CDNF) (Peterson and Nutt, 2008, Petrova et al., 2003, Voutilainen et al., 2009). These factors appear to be more selective and effective for dopaminergic neurons than other known trophic factors, such as glial-derived neurotrophic factor GDNF (Hoffer, 2011) and brain-derived neurotrophic factor BDNF (Nagahara and Tuszynski, 2011). CDNF is abundantly produced in various brain tissues of adult mice, such as the cortex, hippocampus, SN, cerebellum and locus coeruleus (Lindholm et al., 2007). Sf9-derived recombinant human CDNF proteins injected into the rat striatum has been shown to exhibit a substantial neuroprotective effect against 6-OHDA lesions. A single dose of CDNF introduced prior to 6-OHDA injection significantly reduced amphetamine-induced turning behavior and almost completely rescued deteriorated DA cells of the SN. Intrastriatal CDNF administration for 4 weeks following 6-OHDA injection restored dopaminergic function and significantly prevented nigral DA neuron degeneration (Lindholm et al., 2007). The report suggested that CDNF could be of great therapeutic potential in treating human PD patients.

Adeno-associated viral (AAV) vectors are predominant viral vectors in gene therapy clinical trials for neurodegenerative diseases (Lu, 2004). Neurotrophic factor-delivered by AAV vectors have shown encouraging promise for PD gene therapy in both animal studies and clinical trials (Mochizuki and Mizuno, 2003). Among the applications of AAV-mediated transgene expression in the central nervous system, the AAV2 vector is most frequently used. AAV2 is effective in transducing neurons, allowing long-term transgene expression, and is associated with minimal host immune responses (Bankiewicz et al., 2006, Yan et al., 2007). In the present study, we constructed an AAV2.CDNF overexpression vector and injected it directly into the adult rat striatum after 6-OHDA treatment to examine whether AAV-mediated CDNF delivery was able to restore long-term behavior changes induced by 6-OHDA lesions. We also examined the substantia nigra dopamine (DA) cell numbers and striatal DAT activity in 6-OHDA parkinsonian rats with or without the administration of AAV2.CDNF.

Section snippets

Plasmid construction and rAAV2 viral vector production

pAAV2-CDNF is a derivative of pSNAV2.0, which is a patent vector of Vector Gene Technology Company Limited (VGTC, Beijing, China), inserted with human CDNF at Age I/Nhe I sites. The AAV2 viruses used in this study, AAV2.eGFP and AAV2.CDNF, both used an overexpression cassette driven by a CMV promoter. Virus production and purification were contracted to the Vector Gene Technology Company Limited using BHK21 as the producer cell line. The obtained viruses were tested to verify clinical grade

Characterization of AAV2.CDNF for long term transduction in rat striatum

PCR was used to amplify the complete human CDNF coding sequence from a cDNA library; the sequence was then cloned into a pSNAV vector and packaged in the AAV2 virus using BHK21 as the producer cell line. To determine whether efficient transduction occurred following viral infection, 293T cells were infected with the obtained AAV2.CDNF virus for 24 h. Little RT-PCR product was observed in naïve cells, while high levels of CDNF mRNA were detected in pAAV2-CDNF and AAV2.CDNF treated cells (Fig. 1b

Discussion

To treat PD, neurotrophic factors are a preferred neurorestorative therapy in patients with significantly compromised nigrostriatal dopamine pathways (Lindholm and Saarma, 2010). Previously, the most promising candidates were GDNF (Aoi et al., 2001, Brizard et al., 2006) and NRTN (Oiwa et al., 2002, Rosenblad et al., 1999), both of which demonstrated neurorestorative effects in 6-OHDA intrastriatally injected rats. However, the preliminary results of clinical trials of these factors in PD

Acknowledgments

This study was supported by the Chinese National Basic Research Program (2011CB504100) and the National Natural Science Foundation of China (31000476).

References (44)

  • A.L. Peterson et al.

    Treatment of Parkinson's disease with trophic factors

    Neurotherapeutics

    (2008)
  • C. Rosenblad et al.

    Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model

    Exp. Neurol.

    (2000)
  • H. Sauer et al.

    Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat

    Neuroscience

    (1994)
  • A.J. Stoessl

    Positron emission tomography in premotor Parkinson's disease

    Parkinsonism Relat. Disord.

    (2007)
  • M.H. Voutilainen et al.

    Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease

    Exp. Neurol.

    (2011)
  • H. Yuan et al.

    Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease

    J. Neurosci. Methods

    (2005)
  • M. Aoi et al.

    Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism

    Restor. Neurol. Neurosci.

    (2001)
  • S. Back et al.

    Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

    Brain Behav.

    (2013)
  • D.J. Brooks

    Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease

    J. Neurol.

    (2000)
  • A.L. Brownell et al.

    Cocaine congeners as PET imaging probes for dopamine terminals

    J. Nucl. Med.

    (1996)
  • E.A. Burton et al.

    Gene therapy progress and prospects: Parkinson's disease

    Gene Ther.

    (2003)
  • F. Cicchetti et al.

    Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging

    Eur. J. Neurosci.

    (2002)
  • Cited by (0)

    1

    The first two authors contributed equally to this article.

    View full text